FIRST@CIRSE

CIRSE 2025 will have the most extensive FIRST@CIRSE sessions ever held, featuring original papers and brand-new, ground-breaking IR studies presented by the researchers.

First data release on vascular IR trials and studies | First data release on various IR trials and studies

FIRST@CIRSE: First data release on vascular IR trials and studies

Saturday, September 13, 11:30-12:30

Moderators: K. Katsanos, J. Kaufman

New insights into the 12 months outcomes from the SUCCESS PTA study – a stratified analysis by lesion location of the performance of a novel sirolimus-eluting balloon in real-world patients with peripheral arterial disease
M. Lichtenberg

Impact of drug-coated vs uncoated devices for infrainguinal endovascular revascularisation in patients with chronic lower limb occlusive disease: Primary results of the SWEDEPAD 1 and SWEDEPAD 2 trials
M. Falkenberg

Safety and efficacy of amber peripheral liquid embolic system: a first-in-HumAn & pivotal study. Stage I.
F. Gómez Muñoz

Safety and efficacy of the OATF® optimal inferior vena cava filter: a first-in-man single-center prospective study
O. Pellerin

Performance of a Sirolimus-Eluting Balloon for the Treatment of Failed Arteriovenous Fistula in Renal Dialysis Patients: Primary Endpoint Results from the SAVE Randomized Controlled Trial
K. Katsanos

FIRST@CIRSE: First data release on various IR trials and studies

Tuesday, September 16, 16:15-17:15

Moderators: L. Patrone, TBD

The HistoSonics system for treatment of primary solid renal tumours using histotripsy: first report of technical success and safety profile from the CAIN trial
T. M. Wah

Safety and feasibility of CT-guided percutaneous radionuclide therapy with the OncoSil™ device in patients with non-progressive locally advanced pancreatic cancer (PANCOSIL): an open-label, single-arm phase 1-2 feasibility study
D. Vos

Cost benefit analysis of selective internal radiation therapy with Y-90 glass microspheres versus drug-eluting bead transarterial chemoembolization for patients with unresectable hepatocellular carcinoma in Italy
L. Crocetti

TALENTACE: A phase 3, open-label, randomized study of on-demand transarterial chemoembolization (TACE) combined with atezolizumab + bevacizumab (Atezo/Bev) or on-demand TACE alone in patients with untreated hepatocellular carcinoma (HCC)
M. Kudo

Biotronik Dynetic-35 cobalt chromium balloon-expandable stent for iliac lesions: 24-month results of the BIONETIC-I multi-center study
M. Brodmann

DOORwaY90: Selective Internal Radiation Therapy using SIR-Spheres Y-90 Resin Microspheres as first-line treatment for unresectable Hepatocellular Carcinoma patients – an interim analysis
C. Kappadath